Advertisement

Adalat pp 167-168 | Cite as

Arterial Calcium Overload: A Cardinal Element in the Development of Arteriosclerosis and Vasoprotection with Calcium Antagonists

  • A. Fleckenstein
  • M. Frey
  • F. Thimm
  • G. Fleckenstein-Grün
Conference paper

Abstract

At present, the antiarteriosclerotic efficacy of calcium (Ca) antagonists, first described in 1971 [1] and subsequently analyzed in a multitude of experimental models on rats by Fleckenstein and coworkers [2–6], is increasingly gaining interest. It is a well-known fact that in arterial walls that are altered by sclerotic processes, two main constituents accumulate: lipids (particularly cholesterol) and Ca. However, the accumulation of lipids has long been incriminated as the primordial pathogenic factor, whereas the concomitant arterial Ca overload was considered a phenomenon of secondary importance. This is rather puzzling, because in 1913, the same year as Anitschkow [7] first produced atheromatous lesions in cholesterol-fed rabbits, Katase [8] depicted calcific incrustation and subsequent destruction of the internal elastic membrane in the arterial walls of guinea pigs and rabbits injected with soluble calcium salts. But Anitschkow’s cholesterol-fed rabbits overshadowed Katase’s observations completely.

Keywords

Calcium Antagonist Human Coronary Artery Atheromatous Lesion Internal Elastic Membrane Calcium Antagonism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Janke J, Hein B, Pachinger O, Leder O, Fleckenstein A (1972) Hemmung arteriosklerotischer Gefäßprozesse durch prophylaktische Behandlung mit MgCl2, KCl und organischen Ca++-Antagonisten (quantitative Studien mit Ca45 bei Ratten). In: Betz E (ed) Vascular smooth muscle. Verh Satellit Symp XXV Internat Congr f Physiol Wissensch Tübingen, Juli 1971, Springer, Berlin Heidelberg New York, pp 71–72CrossRefGoogle Scholar
  2. 2.
    Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G (1985) Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists. Am J Cardiol 56:3H-14HPubMedCrossRefGoogle Scholar
  3. 3.
    Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G (1985) Interdependence of antihypertensive, anticalcinotic and antiarteriosclerotic effects of calcium antagonists — model experiments on spontaneously hypertensive rats. In: Fleckenstein A, van Breemen C, Groß R, Hoffmeister F (eds) Cardiovascular effects of dihydropyridine-type calcium antagonists and agonists. Bayer-Symposium IX, Springer, Berlin Heidelberg New York, Tokyo pp 480–499CrossRefGoogle Scholar
  4. 4.
    Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G (1987) The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends Pharmacol Sei 8:496–501CrossRefGoogle Scholar
  5. 5.
    Fleckenstein A, Fleckenstein-Grün G, Frey M, Zorn J (1989) Calcium antagonism and ACE-inhibition. Two outstandingly effective means of interference with cardiovascular calcium overload, high blood pressure, and arteriosclerosis in spontaneously hypertensive rats. Am J Hyperts 2:194–204Google Scholar
  6. 6.
    Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G (1990) Calcium, a neglected key factor in hypertension and arteriosclerosis. Experimental vasoprotection with calcium antagonists or ACE inhibitors. In: Laragh JH, Brenner BM (eds) Hypertension: pathophysiology, diagnosis, and management. Raven, New York, pp 471–509Google Scholar
  7. 7.
    Anitschkow N, Chałatów S (1913) Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse. Zentralbl Allg Pathol Anat 14:1–9Google Scholar
  8. 8.
    Katase A (1913) Experimentelle Verkalkung am gesunden Tiere. Beitr Pathol Anat Allg Pathol 57:516–550Google Scholar
  9. 9.
    Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grün G (1990) Excessive mural calcium overload — a predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc Drugs Ther 4:1005–1014PubMedCrossRefGoogle Scholar
  10. 10.
    Fleckenstein A, Fleckenstein-Grün G (1980) Cardiovascular protection by Ca antagonists. Eur Heart J 1:15–21PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • A. Fleckenstein
    • 1
  • M. Frey
    • 1
  • F. Thimm
    • 1
  • G. Fleckenstein-Grün
    • 1
  1. 1.Study Group for Calcium Antagonism Physiological InstituteUniversity of FreiburgFreiburgGermany

Personalised recommendations